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Abstract
Background: Age-related sarcopenia is a disease state of loss of muscle mass and strength that affects physical
function and mobility leading to falls, fractures, and disability. The need for therapies to treat age-related
sarcopenia has attracted intensive preclinical research. To facilitate the discovery of these therapies, we have
developed a non-invasive rat muscle functional assay system to efficiently measure muscle force and evaluate the
efficacy of drug candidates.
Methods: The lower leg muscles of anesthetized rats are artificially stimulated with surface electrodes on the knee
holders and the heel support, causing the lower leg muscles to push isometric pedals that are attached to force
transducers. We developed a stimulation protocol to perform a fatigability test that reveals functional muscle
parameters like maximal force, the rate of fatigue, fatigue-resistant force, as well as a fatigable muscle force index.
The system is evaluated in a rat aging model and a rat glucocorticoid-induced muscle loss model
Results: The aged rats were generally weaker than adult rats and showed a greater reduction in their fatigable
force when compared to their fatigue-resistant force. Glucocorticoid treated rats mostly lost fatigable force and
fatigued at a higher rate, indicating reduced force from glycolytic fibers with reduced energy reserves.
Conclusions: The involuntary contraction assay is a reliable system to assess muscle function in rodents and can
be applied in preclinical research, including age-related sarcopenia and other myopathy.
Keywords: fatigue, Boltzmann equation, dexamethasone, castration.
Background
Age-related sarcopenia is associated with significant loss of
muscle mass and muscle strength upon aging. The etiol-
ogy of age-related sarcopenia is believed to be multi-fac-
torial and includes aging, disease, inflammation, increased
oxidative stress, reduced physical activity, malnutrition,
hormone deficiencies, muscle structural changes, and
motor unit remodeling [1]. By 2050, it is predicted that
the worldwide population ≥ 60 years of age will more than
triple from 600 million at present to 1.9 billion. This is
likely to result in a growing need to treat aging related
diseases such as age-related sarcopenia [2].
Although, there is no widely accepted clinical defini-
tion of age-related sarcopenia, several diagnostic proto-
cols have been developed such as handgrip strength,
knee extension isometric torque, lower extremity muscle
power, weight loss, gait speed, physical activity question-
naires, dynamometer studies, and a standardized physi-
cal performance test battery of standing, walking, and
stair climbing [3-10]. Generally, clinical tests for skeletal
muscle function in sarcopenic patients are frequently
performed on the lower extremities since the extremities
show the most significant muscle degeneration during
aging and because sarcopenia is frequently associated
with reduced blood flow in these limbs [11,12].
Aged muscles show significant alterations to their
architecture [13], underscored by a general loss of muscle
fibers and a decrease in fiber size accompanied by motor
unit remodeling. This remodeling predominantly affects
fatigable glycolytic type II fibers that make the greatest
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any medium, provided the original work is properly cited.contribution to strength [14]. Recently, several potential
age-related sarcopenia targets and therapeutics have been
identified and investigated, including androgen receptors,
myostatin, TGF-b1 and Notch-1 signaling, multiple
histone deacetylases, Angiotensin II pathway signaling,
and b2-adrenoreceptor activators [15-19]. Some success
in early phase clinical trials has been reported with ACE
(Angiotensin converting enzyme) inhibitors [20] and
selective androgen receptor modulators [21].
The animal models used in this report are dexametha-
sone (Dex) treated rats and naive aged rats. Dex is potent
glucocorticoid and treatment of rats with Dex to induce
myopathy is a frequently used model to evaluate drug
candidates which affect muscle size or function [22,23].
Glucocorticoids, induce acute myopathy within a few days
and reduce muscle force predominately due to atrophy of
type II muscle fibers, without affecting specific muscle
force [24]. While Dex-induced muscle atrophy selectively
affects fast fibers, there are no gross changes in architec-
ture which may explain the lack of alteration in specific
force.
Aging rats start losing muscle mass in their lower
extremities at ~18 months and become significantly
weaker than adult rats of comparable size over a period
of 4-6 months. Aging rats have many characteristics in
common with humans regarding progressive changes in
skeletal muscle architecture and selective loss of Type II
alpha motor neurons and fast fibers with age [25,26]. As
described above, therapeutic agents which affect muscle
size in humans also increase muscle size and function in
aging rats and mice [19,27-29].
Most preclinical approaches to evaluate potential thera-
peutics in animals have been focused on improving mus-
cle structure and identifying biomarkers. However, the
need for a reliable functional muscle assay that has suffi-
cient throughput to be a practical tool in preclinical
rodent studies has met with limited success. Preclinical
animal studies to measure muscle function include grip
strength, rotarod performance, treadmill performance,
dynamometer performance, and in-vitro muscle func-
tional assays of isolated muscle fibers.
The interpretation of results from most of the in-vivo
assays is complicated by inherent variability and is lim-
ited by uncontrollable voluntary behavioral factors and in
many cases, requires training and acclimation [30,31].
These factors can be especially difficult for older animals
because both the reflexive response and the learning pro-
cess in aged animals can be compromised compared to
adult animals. In-vitro force measurements on electrically
stimulated muscle fiber requires invasive fiber isolation
procedures with lower throughput and are only applic-
able to study endpoints [32,33]. The rodent dynam-
ometer evaluates isometric muscle force as well as force-
velocity and force-power relationships under isokinetic
and isotonic conditions [34-36]. A non-invasive hydraulic
muscle assay system was developed to monitor muscle
force using external electrode stimulation, a hydraulic
piston system, and a pressure sensor [37]. The later two
assay systems are conducted under anesthetic condition,
hence eliminate voluntary factors during force measure-
ment. Furthermore, the team of Giannesini et al stimu-
lated muscle contraction using non-invasive external
electrodes. The non-invasive external electrode stimula-
tion enables the performance of multiple studies on the
same animals; it induces contractions of more than one
m u s c l eg r o u ps ot h a ti ta l l o w se v a l u a t i o no fm u s c l e
strength resulting from the combination of these forces.
It is not suitable for characterization of individual muscle
contraction. The involuntary assay systems are not com-
mercially available and the throughput remains low. We
aimed to develop a higher throughput involuntary con-
traction assay system that enables routine in-vivo studies
to screen compound efficacy to support drug discovery.
We developed the rodent involuntary muscle contrac-
tion system that electrically stimulates the lower hind
limb muscles of anesthetized rats and measures the iso-
metric force output by placing force transducers behind
the foot pedals. This system eliminates animal voluntary
factors and measures muscle functionality.
By using the custom built animal assay stage and the
automated data analysis, this system has been optimized
to have reasonable throughput for supporting routine
animal studies in drug discovery. We wanted to deter-
mine whether this system was robust and sensitive
enough to detect muscle performance changes in two dif-
ferent preclinical models of muscle loss. If this system
met these criteria then it would be widely applicable for
discovery of therapeutics to treat diseases and conditions
of muscle loss.
Methods
Animals and Animal Models
All animals were housed under equal day and night
cycles and were fed a standard diet ad libitum.A l la n i -
mal procedures were approved by the Merck Research
Laboratories-West Point, PA IACUC in accordance with
the National Research Council Guide for the Care and
Use of Laboratory Animals.
Aged and adult rat model
Aged and adult retired male breeder Sprague Dawley rats
at 24 months old (Charles River, Wilmington, MA) and 9
to 11 months old (Taconic, Hudson, NY) respectively
were examined. The expected life span of these rats is
approximately 30 months. They start to show mortality
by 18 months of age and show higher mortality rates and
significant muscle loss by ~24 month of age.
The body composition of the adult retired breeder rats
was determined by quantitative NMR (qNMR) and
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body compositions of 315 aged rats were also deter-
mined by qNMR and there was a high degree of varia-
bility among the animals so they were sub-grouped into
heavy, light, lean, and fat body type groups. Six indivi-
dual rats were allocated to each group based on body
weight, lean mass, fat mass, fat/lean ratio, and fat/body
weight ratio. The aged heavy and aged light animals
were differentiated based on their body weight being
significantly greater or less, respectively, than the aver-
age of the aged rats and the adult rats (average body
weight for adult, aged heavy and aged light animals was
593 ± 14 g, 766 ± 11 g and 574 ± 17 g, respectively).
The aged fat animals were differentiated based on hav-
ing a significantly different distribution of lean and fat
(the fat/lean ratio was 21% for adult rats, 21% for aged
lean rats, 42% for aged heavy, 40% for aged light and
55% for aged fat). The lean animals were differentiated
based on having a similar weight and body composition
to the adult rats.
Dexamethasone treated rat model
Male retired breeder Sprague-Dawley rats (10 - 12 month
old, ~550 g) (Taconic, Hudson, NY) were implanted with
90 day delayed release pellets containing either 1.5 mg
d e x a m e t h a s o n et oa c h i e v ead o s eo f0 . 0 3m g / d a yo rp l a -
cebo pellet (Innovative Research of America, Sarasota, FL).
Rats were tested 11 days after pellet implantation, since
this was the time period when the most profound muscle
atrophy was observed.
Body Composition Measurements
In live animals, fat mass and lean mass were measured
using the EchoMRI 700™ following the manufacturer’s
guidelines (Echo Medical Systems, Houston, TX). Animals
are weighed on a scale to determine total body mass and
then subjected to necropsy, by CO2 euthanasia, at the end
of each study. The plantarflexor muscle group was dis-
sected from both legs and the right side muscles are
weighed. A post hoc analysis using the Tukey-Kramer test
was used for multiple group comparisons.
Involuntary Contraction Assay
The involuntary contraction assay stage was built using
building blocks from a construction set (Fischertechnik
®, Germany) on top of a base plate. It also includes a gas
anesthesia nose cone, two 1/8” stainless steel rod elec-
trode (one at the knee and one at the heel), one 1/8”
stainless steel rod foot holder, two foot pedals with hinge
on the base to a stainless rod, and two force transducers
(FT10, Grass Instruments, West Warwick, RI) that are
attached to the foot pedals. The rats are anesthetized
with isoflurane (3-5%) and are placed belly up on the
stage. Hind paws are placed on the pedals with the femur
bone roughly perpendicular to the tibia bone (Figure 1;
Figure 2A and Figure 2B). The hind limb is secured
tightly against the foot pedal by the electrode rods on the
knee and beneath the heel and a stainless rod on the top
of the ankle. The angle of the pedal-force transducer
assembly is adjustable to allow for a natural position
(usually ~20o backward) of the ankle joint. The place-
ment and level of stimulation of the external electrodes
on the knee and heel was optimized to result in genera-
tion of maximum observable force. This stimulation
results in movement of the foot on the foot pedal which
presses against the force transducer.
Stimulation waveforms were generated by an analog
constant voltage stimulator (S48, Grass Instruments, West
Warwick, RI) and a 10 Volt signal was split and sent two
DS3 constant current isolated stimulators (Digitimer,
Hertfordshire, England), where the amplitude of the sti-
mulation was set in mA. Each DS3 stimulates one leg.
Force transducer signals were amplified (P122, Grass
Instruments, Warwick, RI), digitized and recorded at 1
kHz (PolyView 16, Grass Instruments, Warwick, RI).
Fatigability Test
To simulate a fatiguing exercise, tetanic contractions were
evoked repeatedly by sending supramaximal square wave
pulse trains to the leg muscles. Stimulation parameters
included pulse duration, pulse frequency, train duration,
train frequency, and stimulation amplitude. Each tetanic
contraction generates a force spike. The maximum force
of each spike was obtained from the recorded raw data
using a custom LabView
® script (National Instruments
Corporation, Austin, TX) and exported as a fatigue envel-
ope (Figure 3) for graphing and further analysis, such as
curve fitting. A two-way ANOVA (force, time) and Bon-
feronni’s post hoc test were used to compare differences
between groups in force during fatiguing stimulation.
Fatigue envelope analysis
Natural muscle aging and glucocorticoid treatment both
result in a preferential loss of type II fibers [38,39]. Curve
analysis was applied to approximate the contributions of
fatiguing fibers (fast fatigable muscle myofibers, type II
fibers) and fatigue-resistant fibers (slow-/non-fatigable
myofibers, type I fibers) to the total force output. The fati-
gue envelope was curve fitted with a Boltzmann equation
that generated four parameters: maximum force (Fmax),
minimum force (Fmin), half fatigue time (time at (Fmax-
Fmin)/2, T50), and fatigue slope (slope of the fatigue
envelope at half fatigue time, SlopeT50) [40]. Fmin was
selected to represent fatigue resistant muscle force and it
was not observed to change significantly during the
recording (Figure 3) [38]. The Fmax and Fmin are defined
as the highest and the lowest muscle forces that are gener-
ated under a specific stimulation protocol. To approximate
the contribution of fatigable muscle force, we took Fmax
Chiu et al. BMC Musculoskeletal Disorders 2011, 12:246
http://www.biomedcentral.com/1471-2474/12/246
Page 3 of 12Figure 1 Diagram of rodent hind limb involuntary contraction assay. The system includes surface electrodes placed at the knee and heel
(a), a foot pedal (b), and a force transducer (e). Contraction of the plantarflexor muscles (f) exerts force onto the transducer (arrow).
Figure 2 Images of the rat involuntary contraction assay stage. The electrodes (a), foot pedal (b), foot holder (d) and foot pedal center of
rotation (c), force transducer (e) and foot pedal-force transducer assembly (h) are labeled on the images.
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the area under the curve to represent a fatigable muscle
force index (F AUCT50; Figure 3).
The indices can be used as a ratio for comparison
between different groups in the same study. One-way
analysis of variance (ANOVA) (a = 0.05 or 0.01) was
used to determine differences between the tested
groups.
Results
Fatigability Test Development
To optimize the stimulation protocol for tetanic force
development, we compared single tetanic stimulations
with different pulse duration and found that pulse dura-
tion of 1 ms at a frequency of 60 Hz and an amplitude
approximately 1.5 times the maximal effective stimula-
tion amplitude, resulted in a reliable supramaximal sti-
mulation and a fully fused tetanus (data not shown). To
optimize the fatigue related stimulation parameters, we
tested four different protocols on ~10-12 month old rats
and generated fatigue envelopes (Figure 4).
The chosen protocol used a train duration of 100 ms
at a train frequency of 1 Hz and produced the most sui-
table fatigue envelope which contained a stable plateau
f o r c ea ta r o u n dt h em a x i m u mf o r c ef o ro v e r3 0sa n d
reached a fatigue-resistant state within 2 min. The other
protocols either needed a longer time to reach fatigue
resistance or were too demanding to represent everyday
muscle use as indicated by the lack of a plateau at maxi-
mum force.
Muscle force changes differently among aged rats with
different body composition
Body weights and qNMR scans of 315 rats at 24 months
of age revealed a number of body composition types. We
assembled four representative groups, i.e. heavy, light, fat,
and lean, to compare with adult10-12 month old rats
(Figure 5). The aged lean group showed no significant
differences in body composition from the 10-12 month
old rats. The weight of the plantarflexor muscle was hea-
vier in the adult rats when compared to all aged rat sub-
groups. The lean subgroup had the next heaviest muscle
f o l l o w e db yt h ef a ts u b g r o u p( F i g u r e6 ) .I ft h ep l a n t a r -
flexor muscle mass is adjusted relative to the body mass
then the aged rat groups are not different from each
other but they are significantly different from the adult
rats (relative plantarflexor mass is 0.0057 g ± 0.0001 g
SEM for adult, 0.0050 g ± 0.0001 g SEM for aged lean,
0.0032 ± 0.0003 g SEM for aged heavy, 0.0044 ± 0.000 g
SEM for aged light, and 0.0036 ± 0.0002 g SEM for aged
fat groups).
The groups were also tested with the involuntary con-
traction assay (train duration of 100 ms at a train fre-
quency of 1 Hz) (Figure 7), in which the adult rats had the
strongest muscle force, followed by the aged lean group.
Using two-way ANOVA analysis (Bonferroni posttests) on
the muscle forces during the first 90 s of contractions the
muscle forces generated by adult rats are significantly
stronger than all aged groups, except the aged-lean group.
Among the aged groups, only the aged-lean group showed
significantly stronger force than the aged-fat group
Figure 3 A typical fatigue envelope recorded from a rat includes a force potentiation phase, followed by a plateau at maximum force,
a fatiguing phase, and a slow-fatiguing or fatigue-resistant phase. Parameters of a fatigue envelope include maximum force (Fmax),
minimum force (Fmin), half fatigue time (T50), slope at T50 (slopeT50), and a fatigable muscle force index (F AUCT50).
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Page 5 of 12Figure 4 Fatigue envelopes for different stimulation protocols. Hind limb muscles are stimulated with trains of either 100 or 200 ms at
either 1 or 2 s intervals. Each stimulation protocol generates different peak forces, plateau force durations, and fatiguing slopes. Both 200 ms
protocols showed the highest maximum force, but no sustainable plateau. The 100 ms at 1 s interval protocol was chosen, because it showed a
sustained force plateau and fatigued the muscles in less than 4 minutes. Error bars are mean ± SEM.
Figure 5 Body composition of adult retired breeder rats (10-12 month old retired breeders (RB)) and 4 subgroups of aged rats (24
months). The subgroups (n = 6 for each subgroup) were screened from 315 aged rats based on body composition parameters (fat mass, lean
mass, body weight (BW)). The lean subgroups body composition is indistinguishable from adult rats. P values are given compared to 10-12
month old RB.
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Page 6 of 12between 20 s and 55 s after the beginning of the stimula-
tion. The heavy, light, and fat groups exhibited weaker
force with no significant differences among the three
groups. With the exception of the aged fat subgroup, the
performance of all groups corresponded to the mass of
their hind limb plantarflexor muscles (Figure 6). To
approximate the forces that were contributed from the
fatigable and fatigue-resistant myofibers, fatigue envelopes
were curve fitted and half fatigue times as well as fatigue
slopes were plotted. All aged rat subgroups showed a
Figure 6 Plantarflexor (gastrocnemius, plantaris, soleus) muscle group weights are shown. P values are given compared to 10-12 month
old RB.
Figure 7 Fatigue envelopes of adult retired breeders (RB) and aged rats of different body composition. The adult rats show the
strongest muscle force while the lean subgroup of the aged rats ranks second. The other aged subgroups are overall weaker but not
significantly different from each other.
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Page 7 of 12significantly reduced Fmax and slope T50 compared to the
adult rats. F AUCT50 was significantly lower in the aged
fat group compared to the adult rats, but there was no sig-
nificant difference in F AUCT50 between the other aged
subgroups and adult rats. Fmin and T50 were not different
between groups (Figure 8). ANOVA analysis of muscle
force from all subgroups at the first 90 s of the stimulation
indicated that adult rats displayed significantly stronger
force compared to the heavy, light, and fat aged subgroups,
however no significant difference was found between the
adult rats and the aged lean subgroup. On the other hand,
the aged lean subgroup had significantly higher force
values than the aged fat subgroup (data not shown).
Muscle force is decreased in a rat model of
dexamethasone induced myopathy
Over two weeks of Dex treatment, rats exhibited a time
dependent decrease in total body mass, lean mass, and
fat mass, with a loss of hind limb muscle mass propor-
tional to the overall loss of lean mass (data not shown).
In this study, after 11 days of Dex treatment, animals had
reductions in total body mass, lean mass, and fat mass of
about 30, 33, and 53% respectively, when compared to
placebo controls (Figure 9). The plantarflexor muscles
were also reduced by 30% as compared with matching
controls (data not shown). Fatigue envelopes showed
similar profiles at baseline (Figure 10 inset); at study end
however, Dex treated rats showed a significantly reduced
f a t i g a b l em u s c l ef o r c e ,c o n sistent with a loss of type II
fibers (Figure 10; Menezes 2007, Seene 2003). Interest-
ingly, Dex treated rats reached the curve center at 50%
fatigue which is significantly faster than control animals
(74 vs. 87 contractions) and they did not show a typical
Fmax plateau around maximal force but instead started
fatiguing right after reaching maximum force. The Dex
treated rats showed reduced muscle performance in all
parameters and the slopeT50 and F AUCT50 were the
most affected parameters (Figure 11).
Discussion
The described non-invasive involuntary muscle contrac-
tion assay allows repeated monitoring of skeletal muscle
isometric force during preclinical drug efficacy studies
in rodents with throughputs of up to 8 animals per
hour. This system measures muscle force on anesthe-
tized animals, which eliminates the voluntary behavior
factor and enables measurement of the functional out-
put of the leg muscles. This assay system is designed to
repetitively and non-invasively monitor rat muscle func-
tionality in response to drug treatment. This non-inva-
sive assay system allows repetitive monitoring of muscle
functionality in the same animal at multiple time points
during a long term study.
There are limitations to the interpretation of changes
in muscle force data from this type of evaluation.
Although the hind limb muscles were stimulated by
Figure 8 Calculated fatigue envelope parameters. Compared to the 10-12 months old retired breeders (RB), the aged subgroups show a
graded Fmax reduction, while reductions of slope T50 and F AUC T50 are more pronounced. No differences were observed between adult rats
and all aged rat subgroups for T50. Error bars indicate mean ± SEM. P values are given compared to 10-12 month old RB.
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Page 8 of 12Figure 9 Changes in body composition of Dex treated 10-12 month old male rats (n = 12). Dex treated rats show significantly decreased
body weight (30%), lean mass (33%), and fat mass (53%) after 11 days when compared to placebo treated rats. P values are given compared to
placebo treated rats.
Figure 10 Changes in fatigue envelopes of Dex treated 10-12 month old male rats (n = 12). The fatigability test, performed before
treating with Dex showed no differences in muscle force (inset). After 11 days of treatment, the Dex treated rats showed a significantly reduced
force plateau (fatigue envelopes from both legs were recorded). Twelve rats from each treatment group were tested and the force generation of
their left and right legs were recorded independently (i.e. n = 24 data sets/group).
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the plantarflexor and the dorsiflexor muscle were fully
activated; this assay measures the sum of forces contrib-
uted by the agonist and antagonist effects of the plantar-
flexor and dorsiflexor muscle groups. The system
provides an indirect measurement of muscle force gen-
erated by contractions of multiple muscles, and is not
designed to assess the force contributions from specific
muscle groups or fiber types. It is expected that some of
the actual muscle force is dissipated by mechanical fric-
tion during transmission to the force transducer and by
the paw/pedal acting as a lever. Nevertheless, the fatigue
envelop generated from the involuntary contraction
assay shares a similar profile with isolated muscle tested
in an organ bath [41,42]. Still, the parameters calculated
from the fatigue envelopes are relative indicators of the
phenotype rather than documenting the true changes of
muscle force.
Using the involuntary contraction assay to perform
muscle fatigue tests provided well defined fatigue envel-
opes that show phases of force potentiation, Fmax pla-
teau, fatiguing, and fatigue resistance, thus providing
information about the amount of fatigable muscle force,
its rate of fatiguing, and the amount of remaining fati-
gue-resistant force for each subject [38]. Similar fatigue
envelopes are frequently used in clinical diagnosis of
muscular diseases and injuries, as well as in a wide array
of basic research studies on isolated mammalian skeletal
muscles [38,42-45]. Most importantly, this approach pro-
mises to bridge the gap between classical preclinical mus-
cle studies and current clinical research [43,45,46].
T h ef a t i g u es l o p e( S l o p eT 5 0 )a n dt h ef a t i g a b l ea r e a
under the curve (F AUCT50) are useful parameters to
describe muscle functionality in this test. The calcula-
tion of functional indices of approximate force contribu-
tions of fatigable and fatigue-resistant muscle fibers may
enable us to distinguish functional drug effects on myo-
fiber subtypes. However, using Fmin as a cutoff to
approximate the contribution of fatigue-resistant muscle
fibers to the total force before the curve center is likely
to result in an underestimate, because those fibers do
show some fatiguing during the latter part of the muscle
fatiguing test. Therefore the fatigable index might also
be higher than estimated. In the Dex study, this effect
might skew the comparison of the functional index
ratios between vehicle and Dex treated groups, since
Fmin is very similar in both groups and therefore rela-
tively larger in the weaker Dex treated rats. Nonetheless,
comparing functional indices and their ratios within a
study should provide relevant information about differ-
ences in fiber type composition of the tested leg
muscles.
Figure 11 Changes in fatigue envelope parameters of Dex treated 10-12 month old male rats (n = 12). Dex treated rats show reductions
in all fatigue envelope parameters, e.g. 25%, 20%, 15%, 50%, and 45% reductions of Fmax, Fmin, half fatigue time (T50), slopeT50, and F AUCT50,
respectively. Error bars indicate mean ± SEM. P values are given compared to placebo treated rats.
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be necessary to refine our approximations. Most aged rats
showed a profound loss of fatigable force and a somewhat
diminished fatigue-resistant force when compared to their
adult counterparts, as indicated by comparing Fmin and F
AUCT50. It has been reported in aging rats that the stron-
ger type II myofibers degenerate faster than the fatigue-
resistant type I [39] and our results are consistent with
these observations, however immunohistochemical char-
acterization of the muscle is needed to confirm the distri-
bution of fiber types. The lean group showed the best
performance among the aged subgroups, while the signifi-
cantly weaker muscle function of the fat group could be
due to a higher infiltration of fat within the muscle archi-
tecture [47]. Dex treated animals showed a significant
reduction in fatigable muscle force but only a relatively
minor reduction of fatigue-resistant force, which confirms
previously published results where type II fibers were sig-
nificantly more affected by Dex treatment than type I
[22,48] and provides support for Dex treatment as a
potential animal model to represent muscle aging. The
lack of an Fmax plateau and a shorter half fatigue time
(T50) could be due to reduced energy resources for type II
fibers, which would agree with reports indicating
decreased glucose uptake and decreased glycogen synth-
esis in Dex treated rats [49].
Conclusions
In summary, the fatigue tests that were performed in the
two different studies, using our custom built involuntary
contraction assay system, provided data that are validated
by the literature. This indicates that the assay system is a
reliable way to assess muscle function in rat. Overall, per-
forming fatigue tests with the involuntary contraction
assay has effectively revealed changes in functional muscle
parameters in preclinical rodent studies and it promises to
be a useful tool to evaluate the efficacy of sarcopenia treat-
ments and may enhance drug discovery for muscular dys-
trophies as well. The described approach could be a
reliable bridge between preclinical and clinical studies,
since it should be translatable to clinical research.
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